WHO Declares Bundibugyo Virus Epidemic a Public Health Emergency of International Concern

On May 17, 2026, the Director-General of the World Health Organization (WHO) officially determined that the ongoing epidemic of Ebola disease caused by the Bundibugyo virus in the Democratic Republic of the Congo and Uganda constitutes a Public Health Emergency of International Concern (PHEIC). This declaration follows extensive consultation with the affected States Parties and highlights the critical need for coordinated global action, even as the situation does not currently meet the criteria for a pandemic emergency under the International Health Regulations (IHR).

Understanding the Bundibugyo Virus (BDBV)

The Bundibugyo virus (BDBV) is a member of the Orthoebolavirus genus. While it is related to the virus that causes Ebola virus disease, it presents unique challenges for public health officials. Most notably, there are currently no approved vaccines or therapeutics specifically for the Bundibugyo virus. The primary strategy for controlling the epidemic centers on aggressive public health interventions, including early detection, isolation, and robust community engagement.

Key Takeaways

• PHEIC Declaration: The WHO has officially designated the BDBV outbreak a public health emergency of international concern to mobilize resources and coordination.
• Current Risk Assessment: As of May 22, 2026, the WHO assesses the risk in the Democratic Republic of the Congo as “Very high” and in Uganda as “High.”
• Response Strategy: Control efforts rely on enhanced surveillance, contact tracing, infection prevention and control (IPC), and safe, dignified burial practices.
• Clinical Challenges: The absence of approved vaccines or therapeutics necessitates a focus on patient-centered supportive care and rapid diagnostic testing.

Strategic Response and Coordination

The WHO has issued temporary recommendations to guide States Parties in their response. These recommendations are tailored based on the level of risk and the presence of documented transmission. Central to these efforts is the establishment of emergency operation centers under the authority of national governments to ensure that response activities are synchronized across sectors.

Surveillance and Laboratory Capacity

Effective control requires decentralized surveillance and laboratory capabilities. The GeneXpert platform is not capable of detecting the Bundibugyo virus. Authorities are being urged to scale up RT-PCR laboratory capacities to ensure timely testing and quick turnaround times for patient care and clinical research. Contact tracing remains a cornerstone of the response, with a mandatory 21-day monitoring period for all individuals exposed to suspected, probable, or confirmed cases.

Community Engagement and Trust

Public health measures are only effective when they are accepted by the communities they are intended to protect. The WHO emphasizes the need for large-scale trust-building interventions. This involves working closely with traditional and religious leaders to ensure that isolation protocols and safe burial practices are implemented in a way that respects cultural norms while preventing further transmission.

Global Readiness and International Travel

For countries that do not have documented cases, the current risk is assessed as “Low.” However, the WHO advises all States Parties to maintain high levels of readiness. This includes:

• Disseminating BVD case definitions to healthcare facilities and travel clinics.
• Establishing mechanisms to detect and assess travelers with unexplained febrile illnesses.
• Providing accurate, up-to-date information to the public regarding exposure risks.

At this time, the WHO does not recommend the suspension of flights or the denial of entry for travelers from affected areas. Instead, the focus remains on implementing exit screenings at points of entry, including airports and ground crossings, to identify potential cases early and prevent the international spread of the virus.

Future Outlook

The situation remains fluid, and the WHO continues to update its evidence-based guidance as the epidemiological landscape evolves. Ongoing efforts to validate diagnostic platforms and advance clinical trials for candidate therapeutics and vaccines are critical to ending this epidemic. By integrating rigorous clinical care with community-led public health strategies, the international community aims to contain the spread of the Bundibugyo virus and protect vulnerable populations in the affected regions.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. For the latest guidance and official updates, please refer to the World Health Organization.